Psomagen, Inc. will perform whole genome sequencing (WGS) on a global cohort of 80,000 patients and research participants to execute GP2's aim to use genetic knowledge to accelerate the path to the development and deployment of therapeutic strategies for Parkinson's Disease (PD). The program will run over the next 2.5 - 3 years using Illumina sequencing instruments and reagents. GP2 is a program supported by the Aligning Science Across Parkinson's (ASAP) initiative managed by the Coalition for Aligning Science and implemented by The Michael J. Fox Foundation for Parkinson's Research (MJFF) and is focused on improving understanding of the genetic architecture of Parkinson's disease and making this knowledge globally relevant.

The program is made up of member organizations and over 160 cohorts collecting samples and data from around the world to create a global research community dedicated to rapidly addressing emerging research needs in PD. GP2 specifically has the goal of including groups traditionally underrepresented in genetics research, to diversify its understanding of PD by focusing on inclusion in the research pipeline. The global initiative is led by Andrew Singleton, PhD and Cornelis Blauwendraat, PhD of the National Institutes of Health.

GP2 cohort samples will start to be processed immediately. Psomagen will utilize the NovaSeq X Plus, Illumina's most powerful high-throughput sequencer, with its 25B flow cell, library preparation kits and analysis software to generate the whole-genome sequencing data.